why choose us

First received: June 08, 2023

Clinical Trial: Limited-duration Teclistamab

Study Status: Completed

Recruit Status: RECRUITING

Condition: Myeloma Multiple

Study Type: INTERVENTIONAL


Official Title: Phase 2, Single-Arm, Non-Inferiority Study Of Limited-Duration Teclistamab For Relapsed Refractory Multiple Myeloma

Brief Summary: This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria, following 6 to 9 months of treatment with teclistamab, a B-cell maturation antigen (BCMA)-directed T-cell engager (anti-BCMAxCD3 bispecific antibody), will be offered monitored drug discontinuation.Teclistamab is typically dosed on a regular schedule (every 1-4 weeks) indefinitely until disease progression…

Read more